US 11,806,550 B2
Method for treating cancerous and pre-cancerous skin
Christopher Baker, Alexandria (AU); Judith Mary Cole, Alexandria (AU); Robert Sinclair, Alexandria (AU); Warren Weightman, Alexandria (AU); Stephen Shumack, Alexandria (AU); Lynda Spelman, Alexandria (AU); and Peter Foley, Alexandria (AU)
Assigned to GenesisCare Ventures Pty Ltd, New South Wales (AU)
Filed by GenesisCare Ventures Pty Ltd, Alexandria (AU)
Filed on Nov. 11, 2022, as Appl. No. 17/985,297.
Application 17/985,297 is a continuation of application No. 17/570,670, filed on Jan. 7, 2022, granted, now 11,654,298.
Application 17/570,670 is a continuation of application No. 17/183,654, filed on Feb. 24, 2021, granted, now 11,253,724, issued on Feb. 22, 2022.
Claims priority of application No. AU2020902243 (AU), filed on Jul. 1, 2020; application No. PCT/AU2020/051242 (WO), filed on Nov. 17, 2020; and application No. PCT/AU2021/050129 (WO), filed on Feb. 15, 2021.
Prior Publication US 2023/0082800 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 5/10 (2006.01); A61K 35/00 (2006.01); A61B 17/3205 (2006.01); A61K 31/513 (2006.01); A61K 31/4439 (2006.01); A61N 5/06 (2006.01); A61P 35/00 (2006.01); A61P 17/02 (2006.01); A61B 18/02 (2006.01); A61B 17/00 (2006.01); A61N 5/067 (2006.01)
CPC A61N 5/10 (2013.01) [A61B 17/3205 (2013.01); A61K 31/4439 (2013.01); A61K 31/513 (2013.01); A61K 35/00 (2013.01); A61N 5/062 (2013.01); A61N 5/0616 (2013.01); A61P 17/02 (2018.01); A61P 35/00 (2018.01); A61B 18/0218 (2013.01); A61B 2017/00761 (2013.01); A61N 5/067 (2021.08); A61N 2005/0663 (2013.01)] 20 Claims
 
1. A method for treating clinical or pre-clinical skin damage in a skin field of a subject, wherein the skin field has been allocated a skin cancerization field index (SCFI) score of at least 1 or a score of equivalent weighting as determined by a process comprising the steps of:
(a) selecting and assessing at least one skin field for
(i) the number of keratoses in the skin field;
(ii) the thickness of the thickest keratosis in the skin field; and
(iii) the proportion of the skin field affected by clinical or subclinical skin damage;
(b) assigning a score of 0 to 3 for assessment (i), a score of 0 to 3 for assessment (ii), and a score of 0 to 5 for assessment (iii) or scores of equivalent weighting for any of (i)-(iii); and
(c) adding the score for assessment (i) to the score for assessment (ii) and then multiplying the sum of those scores by the score for assessment (iii) to obtain the SCFI score;
the method for treating comprising:
(A) treating the skin field with a field therapy when the SCFI score is 10 or greater or a score of equivalent weighting; or
(B) treating the skin field with a lesional therapy when the SCFI score is 1 to 9 or a score of equivalent weighting.